Literature DB >> 17954663

Eliminating unenhanced CT when evaluating abdominal neoplasms in children.

Eduardo Just da Costa e Silva1, Gisélia Alves Pontes da Silva.   

Abstract

OBJECTIVE: The purpose of our study was to evaluate a CT protocol that eliminates the unenhanced phase for imaging pediatric abdominal neoplasms.
MATERIALS AND METHODS: We retrospectively performed a case series study of all the abdominal CT scans on children and adolescents found in our archives. Two radiologists separately evaluated each CT scan twice. The radiologists were separately asked to formulate the most probable diagnosis and to decide whether tumor calcification was present. The first evaluation was performed without the unenhanced phase and the second was done with both the unenhanced and the contrast-enhanced scans. The agreement between the two methods, and that between each method and the histopathologic results, were measured using kappa statistics. The sensitivity and specificity of each method for diagnosing the more frequent neoplasms were also measured. The sensitivity and specificity of the contrast-enhanced CT scans were assessed for detecting calcification without reference to the unenhanced scan.
RESULTS: A total of 131 CT scans were evaluated. The agreement between diagnoses from the two methods was almost perfect for both radiologists (kappa = 0.97 and 0.99). No statistically significant difference was seen between the two methods and the histopathologic results. The sensitivity and specificity of the two methods for the most frequent neoplasms were similar. The evaluations without the unenhanced phase showed good sensitivity and specificity for tumor calcifications.
CONCLUSION: CT protocols without the unenhanced phase are a viable alternative for evaluating abdominal neoplasms in children and adolescents.

Entities:  

Mesh:

Year:  2007        PMID: 17954663     DOI: 10.2214/AJR.07.2154

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  8 in total

Review 1.  Multidetector CT in children: current concepts and dose reduction strategies.

Authors:  Rutger A J Nievelstein; Ingrid M van Dam; Aart J van der Molen
Journal:  Pediatr Radiol       Date:  2010-06-10

Review 2.  What, why, and when we image: considerations for diagnostic imaging and clinical research in the Children's Oncology Group.

Authors:  Gregory H Reaman
Journal:  Pediatr Radiol       Date:  2008-12-16

Review 3.  Pediatric liver tumors--a pictorial review.

Authors:  Priyanka Jha; Soni C Chawla; Sidhartha Tavri; Chirag Patel; Charles Gooding; Heike Daldrup-Link
Journal:  Eur Radiol       Date:  2008-08-06       Impact factor: 5.315

Review 4.  Imaging of Wilms tumor: an update.

Authors:  Sabah E Servaes; Fredric A Hoffer; Ethan A Smith; Geetika Khanna
Journal:  Pediatr Radiol       Date:  2019-10-16

5.  Detection of preoperative wilms tumor rupture with CT: a report from the Children's Oncology Group.

Authors:  Geetika Khanna; Arlene Naranjo; Fredric Hoffer; Elizabeth Mullen; James Geller; Eric J Gratias; Peter F Ehrlich; Elizabeth J Perlman; Nancy Rosen; Paul Grundy; Jeffrey S Dome
Journal:  Radiology       Date:  2012-11-28       Impact factor: 11.105

6.  Excess of Radiation Burden for Young Testicular Cancer Patients using Automatic Exposure Control and Contrast Agent on Whole-body Computed Tomography Imaging.

Authors:  Hannele Niiniviita; Jarmo Kulmala; Tuukka Pölönen; Heli Määttänen; Hannu Järvinen; Eeva Salminen
Journal:  Radiol Oncol       Date:  2017-02-26       Impact factor: 2.991

7.  Triple-phase abdomen and pelvis computed tomography: standard unenhanced phase can be replaced with reduced-dose scan.

Authors:  Łukasz Waszczuk; Maciej Guziński; Jerzy Garcarek; Marek Sąsiadek
Journal:  Pol J Radiol       Date:  2018-04-22

8.  Relapsed Wilms' Tumor Presenting as Metastasis to the Zygoma.

Authors:  Ryan Thibodeau; Abtin Jafroodifar; Marlon Coelho; Hsin Kwung Li; Lorenzo Gitto; Daniel J Zaccarini; Mary McGrath
Journal:  Radiol Case Rep       Date:  2021-06-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.